Board & Executive

David Lawrence is Non Executive Chairman of Ambicare. David was previously CFO of Acambis PLC, a LSE and Nasdaq listed company which is now part of Sanofi, with responsibility for Finance, Strategy, Investor Relations and Business Development.

Before Acambis he was VP Finance of Chiron Vaccines which is now part of Novartis. David spent thirteen years with GlaxoSmithKline, latterly as VP - Financial Management R&D. David is currently CEO of Tayside Flow Technologies Ltd, a private, VC funded medical device company.

Dr Ian T Muirhead is CEO of Ambicare. Ian has worked extensively in early stage, university spin-out technology companies and led the strategy, business plan development and fundraising for Ambicare prior to joining the company full time in Jan 2008.

Previously he has held director, senior management and business development posts in a range of companies including; CEO of Terahertz Photonics Ltd, a Venture Capital backed university spin out, and Business Development roles in the multinational ST Microelectronics and VISION Ltd, a company which went from university spin-out to IPO.

Ian has wide experience of working with multidisciplinary technologies, and immediately prior to joining Ambicare with Bionsensia leading the development and commercialisation of a portable product for the roadside testing of drugs of abuse using saliva.

Dr Andrew McNeill is Director and Principal Scientist. Andrew has been instrumental in the development of the Ambicare products, CE marking and company accreditation to ISO 13485. Andrew previously worked as part of a pan-European consortium of academic institutions and companies and obtained a PhD in molecular electronic devices.

In 2003 he moved to St Andrews to work as a post-doctoral researcher in the area of phototherapy before joining Ambicare Health. Andrew also currently holds an honorary research fellowship at Ninewells Hospital Dundee.

Professor Ferguson is Consultant Dermatologist and Head of the University Department of Dermatology in Dundee; he is also responsible for the Scottish Photobiology Diagnostic and Treatment Advice Unit, which houses the Scottish Photodynamic Therapy Centre. His MD thesis was on the subject of Drug-induced Photosensitivity.

Professor Samuel leads the Organic Semiconductor Centre at the University of St Andrews. His research focusses on organic semiconductors and their applications, with particular emphasis on light-emission and measurement.

Recent research highlights include the development of the world’s most efficient solution-processed light-emitting diodes (LEDs), compact plastic lasers, and the use of organic LEDs in medicine in collaboration with Prof Ferguson.

His work is internationally recognised and he has published more than 250 articles in the scientific literature.